Biologic therapies available for pediatric patients with asthma – Consumer Health News
MONDAY October 18, 2021 (HealthDay News) – Biologic therapies are available for pediatric patients with asthma and allergic skin conditions, according to a clinical report published online on October 18 in Pediatrics.
Heather Hoch De Keyser, MD, of the University of Colorado Anschutz, and colleagues reviewed the current literature on biologics in the treatment of children with asthma and allergic skin conditions.
The authors note that there are currently several biologics available to treat moderate to severe persistent asthma in children and adults. Omalizumab, an anti-immunoglobulin (Ig) E agent, is indicated in people 6 years of age and older with moderate to severe persistent asthma, positive allergy tests and incomplete control with an inhaled corticosteroid . Mepolizumab and benralizumab, both anti-interleukin (IL) -5 agents, and dupilumab, an anti-IL-4 receptor agent, are indicated for severe eosinophilic asthma that does not respond to other therapies. from Steps 4 to 5 of the Global Asthma Initiative (GINA). in individuals 12 years of age or older. Reslizumab, another anti-IL-5 agent, is indicated for severe eosinophilic asthma in people 18 years of age or older. Providers should be aware of the risk of anaphylaxis associated with many biologics, especially omalizumab and reslizumab. Biologics are also being investigated for the treatment of allergic skin diseases, such as urticaria and atopic dermatitis, in children.
“Researchers should focus on the appropriate biomarkers (including circulating IgE and eosinophils, as well as other biomarkers yet to be determined), as well as other patient-oriented factors to enable the choice of the right biologic for the right patient at the right time, write the authors.
Two authors have revealed financial ties to the pharmaceutical industry.